PMID: 12505105Dec 31, 2002Paper

A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia

Archives of Medical Research
Cynthia S PalmerD Revicki


Schizophrenia afflicts approximately 0.7% of Mexican citizens during their lifetime. This study explored whether the difference in clinical efficacy and safety between atypical antipsychotics and conventional neuroleptics results in decreases in use and cost of medical services in Mexico, offsetting the higher price of atypical antipsychotics. A U.S. decision analytic Markov model was adapted for use in Mexico to determine cost-effectiveness of treatments and outcomes that Mexican patients with schizophrenia may experience over a 5-year period when treated with olanzapine, haloperidol, or risperidone. Model parameter estimates were based on clinical trial data, published medical literature, and where needed, clinician judgment. Direct medical costs were incorporated into the model and outcomes were estimated using lack of relapse and clinical outcomes based on the Brief Psychiatric Rating Scale (BPRS) as effectiveness indicators. All costs are reported in Mexican pesos. Over a 5-year period, the cost of treating schizophrenia ranged from 196,620 pesos per patient initiating therapy with haloperidol to 226,670 pesos per patient beginning therapy with risperidone. Olanzapine was estimated to have slightly better non-relapse and B...Continue Reading


Oct 15, 1991·Biological Psychiatry·M HarrowJ Sands
Apr 15, 1990·Biological Psychiatry·C Z LemusT B Cooper
Jan 29, 1987·The New England Journal of Medicine·S G Pauker, J P Kassirer
Jul 1, 1994·Medical Care·F A SonnenbergD L Kent
Jan 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·L M Davies, M F Drummond
Jan 1, 1995·Schizophrenia Bulletin·L B DixonJ Levine
Jan 1, 1995·Schizophrenia Bulletin·D Umbricht, J M Kane
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Sep 1, 1995·International Clinical Psychopharmacology·D E Casey
Jan 1, 1997·Clinical Therapeutics·M Knapp, S Kavanagh
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley

❮ Previous
Next ❯


Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Claire AdvokatJoseph E Comaty
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
Jul 26, 2012·Health Economics Review·Antonio J García-RuizMiguel A Casado
Aug 26, 2014·American Journal of Preventive Medicine·Frances L Lynch
May 24, 2007·Journal of Evaluation in Clinical Practice·Mark Bounthavong, Mark P Okamoto
Nov 8, 2006·Acta Psychiatrica Scandinavica. Supplementum·P Gutierrez-RecachaJ L Ayuso-Mateos
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Taehwan Park, Karen M Kuntz
May 3, 2016·Revista colombiana de psiquiatría·Hoover Quitian ReyesCarlos Gómez Restrepo
Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Anita Patel
Jun 15, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Ben F M WijnenJoran Lokkerbol
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi
Aug 12, 2009·Revista de saúde pública·Leandro Mendonça LindnerGeder Evandro Motta Grohs

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Psychiatric Services : a Journal of the American Psychiatric Association
John M DavisIra D Glick
European Psychiatry : the Journal of the Association of European Psychiatrists
L Hosák, R Bahbouh
© 2021 Meta ULC. All rights reserved